Assertio Therapeutics Stock Beta

ASRT Stock

USD 0.79 0.01 1.25%

Assertio Therapeutics fundamentals help investors to digest information that contributes to Assertio Therapeutics' financial success or failures. It also enables traders to predict the movement of Assertio Stock. The fundamental analysis module provides a way to measure Assertio Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Assertio Therapeutics stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Assertio Therapeutics Company Beta Analysis

Assertio Therapeutics' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.

Beta

Covariance

Variance

More About Beta | All Equity Analysis

Current Assertio Therapeutics Beta

0.84

Most of Assertio Therapeutics' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Assertio Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Assertio Beta Driver Correlations

Understanding the fundamental principles of building solid financial models for Assertio Therapeutics is extremely important. It helps to project a fair market value of Assertio Stock properly, considering its historical fundamentals such as Beta. Since Assertio Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Assertio Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Assertio Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Short Term Investments	Common Stock	Long Term Debt	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Long Term Investments	Intangible Assets	Capital Surpluse	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.74	0.74	0.33	0.6	0.76	0.98	0.59	0.85	0.49	0.56	0.96	0.87	0.62	-0.82	-0.24	0.93	-0.2	0.88	0.61	0.42	-0.31	-0.19
Total Stockholder Equity	0.74		0.21	0.36	0.57	0.49	0.59	0.86	0.7	0.61	0.49	0.62	0.55	0.52	-0.27	-0.31	0.5	-0.17	0.51	0.48	0.33	-0.08	-0.29
Net Debt	0.74	0.21		0.09	0.39	0.66	0.82	-0.07	0.6	0.15	0.22	0.86	0.66	0.4	-0.97	0.04	0.93	-0.01	0.84	0.44	0.24	-0.25	-0.04
Retained Earnings	0.33	0.36	0.09		0.29	-0.23	0.29	0.41	0.49	0.65	0.68	0.35	0.54	-0.06	-0.1	0.53	0.21	-0.88	0.23	0.69	0.92	-0.83	-0.42
Accounts Payable	0.6	0.57	0.39	0.29		0.39	0.56	0.42	0.76	0.72	0.37	0.62	0.44	0.45	-0.42	-0.09	0.53	-0.19	0.64	0.77	0.22	-0.18	-0.05
Net Receivables	0.76	0.49	0.66	-0.23	0.39		0.76	0.3	0.63	0.19	0.27	0.75	0.51	0.77	-0.73	-0.49	0.78	0.22	0.8	0.28	-0.15	0.17	0.04
Total Liab	0.98	0.59	0.82	0.29	0.56	0.76		0.45	0.81	0.41	0.53	0.97	0.88	0.59	-0.91	-0.2	0.97	-0.19	0.91	0.59	0.4	-0.35	-0.14
Total Current Assets	0.59	0.86	-0.07	0.41	0.42	0.3	0.45		0.56	0.58	0.58	0.43	0.5	0.49	-0.05	-0.3	0.26	-0.31	0.28	0.39	0.38	-0.21	-0.17
Short Term Debt	0.85	0.7	0.6	0.49	0.76	0.63	0.81	0.56		0.79	0.61	0.88	0.76	0.56	-0.64	-0.03	0.77	-0.38	0.84	0.88	0.48	-0.41	-0.17
Short Term Investments	0.49	0.61	0.15	0.65	0.72	0.19	0.41	0.58	0.79		0.73	0.5	0.49	0.3	-0.18	0.22	0.33	-0.63	0.48	0.88	0.59	-0.49	-0.24
Common Stock	0.56	0.49	0.22	0.68	0.37	0.27	0.53	0.58	0.61	0.73		0.53	0.7	0.38	-0.32	0.17	0.41	-0.82	0.49	0.67	0.76	-0.63	-0.3
Long Term Debt	0.96	0.62	0.86	0.35	0.62	0.75	0.97	0.43	0.88	0.5	0.53		0.85	0.61	-0.89	-0.08	0.97	-0.23	0.93	0.67	0.44	-0.38	-0.15
Property Plant Equipment	0.87	0.55	0.66	0.54	0.44	0.51	0.88	0.5	0.76	0.49	0.7	0.85		0.38	-0.76	-0.1	0.82	-0.48	0.77	0.66	0.66	-0.55	-0.15
Current Deferred Revenue	0.62	0.52	0.4	-0.06	0.45	0.77	0.59	0.49	0.56	0.3	0.38	0.61	0.38		-0.48	-0.41	0.55	0.05	0.53	0.24	-0.09	-0.07	0.19
Net Tangible Assets	-0.82	-0.27	-0.97	-0.1	-0.42	-0.73	-0.91	-0.05	-0.64	-0.18	-0.32	-0.89	-0.76	-0.48		0.11	-0.97	0.05	-0.87	-0.46	-0.25	0.3	0.03
Long Term Investments	-0.24	-0.31	0.04	0.53	-0.09	-0.49	-0.2	-0.3	-0.03	0.22	0.17	-0.08	-0.1	-0.41	0.11		-0.15	-0.58	-0.1	0.28	0.54	-0.48	-0.19
Intangible Assets	0.93	0.5	0.93	0.21	0.53	0.78	0.97	0.26	0.77	0.33	0.41	0.97	0.82	0.55	-0.97	-0.15		-0.1	0.93	0.56	0.33	-0.29	-0.12
Capital Surpluse	-0.2	-0.17	-0.01	-0.88	-0.19	0.22	-0.19	-0.31	-0.38	-0.63	-0.82	-0.23	-0.48	0.05	0.05	-0.58	-0.1		-0.19	-0.65	-0.9	0.77	0.34
Long Term Debt Total	0.88	0.51	0.84	0.23	0.64	0.8	0.91	0.28	0.84	0.48	0.49	0.93	0.77	0.53	-0.87	-0.1	0.93	-0.19		0.69	0.32	-0.2	-0.17
Short Long Term Debt	0.61	0.48	0.44	0.69	0.77	0.28	0.59	0.39	0.88	0.88	0.67	0.67	0.66	0.24	-0.46	0.28	0.56	-0.65	0.69		0.66	-0.56	-0.25
Net Invested Capital	0.42	0.33	0.24	0.92	0.22	-0.15	0.4	0.38	0.48	0.59	0.76	0.44	0.66	-0.09	-0.25	0.54	0.33	-0.9	0.32	0.66		-0.79	-0.42
Net Working Capital	-0.31	-0.08	-0.25	-0.83	-0.18	0.17	-0.35	-0.21	-0.41	-0.49	-0.63	-0.38	-0.55	-0.07	0.3	-0.48	-0.29	0.77	-0.2	-0.56	-0.79		0.18
Capital Stock	-0.19	-0.29	-0.04	-0.42	-0.05	0.04	-0.14	-0.17	-0.17	-0.24	-0.3	-0.15	-0.15	0.19	0.03	-0.19	-0.12	0.34	-0.17	-0.25	-0.42	0.18

Click cells to compare fundamentals

In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.

Competition

Predict Assertio Therapeutics

In accordance with the recently published financial statements, Assertio Therapeutics has a Beta of 0.835. This is 2.91% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.

Assertio Beta Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Assertio Therapeutics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Assertio Therapeutics could also be used in its relative valuation, which is a method of valuing Assertio Therapeutics by comparing valuation metrics of similar companies.

Assertio Therapeutics is currently under evaluation in beta category among its peers.

Assertio Therapeutics Institutional Holders

Institutional Holdings refers to the ownership stake in Assertio Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Assertio Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Assertio Therapeutics' value.

		Shares
Ubs Group Ag	2024-12-31	459.7 K
Bridgeway Capital Management, Llc	2024-12-31	455.3 K
Empowered Funds, Llc	2024-12-31	455.3 K
Acadian Asset Management Llc	2024-12-31	424.1 K
Cm Management, Llc	2024-12-31	400 K
Perritt Capital Management Inc.	2024-09-30	390.1 K
State Street Corp	2024-12-31	366.9 K
Squarepoint Ops Llc	2024-12-31	232.2 K
Northern Trust Corp	2024-12-31	227.2 K
Nantahala Capital Management, Llc	2024-12-31	8.1 M
Vanguard Group Inc	2024-12-31	4.4 M

As returns on the market increase, Assertio Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Assertio Therapeutics is expected to be smaller as well.

Assertio Fundamentals

	Return On Equity	-0.42
	Return On Asset	-0.0144
	Profit Margin	(0.54) %
	Operating Margin	(0.09) %
	Current Valuation	27.23 M
	Shares Outstanding	95.34 M
	Shares Owned By Insiders	2.47 %
	Shares Owned By Institutions	38.46 %
	Number Of Shares Shorted	5.73 M
	Price To Earning	4.93 X
	Price To Book	0.58 X
	Price To Sales	0.60 X
	Revenue	152.07 M
	Gross Profit	138.29 M
	EBITDA	(222.45 M)
	Net Income	(331.94 M)
	Cash And Equivalents	52.26 M
	Cash Per Share	1.09 X
	Total Debt	40.91 M
	Debt To Equity	0.49 %
	Current Ratio	1.00 X
	Book Value Per Share	1.38 X
	Cash Flow From Operations	49.6 M
	Short Ratio	14.28 X
	Earnings Per Share	(4.94) X
	Price To Earnings To Growth	1.00 X
	Target Price	3.15
	Number Of Employees	53
	Beta	0.84
	Market Capitalization	81.8 M
	Total Asset	286.42 M
	Retained Earnings	(651.54 M)
	Working Capital	77.62 M
	Current Asset	5.15 M
	Current Liabilities	492.4 K
	Net Asset	286.42 M

About Assertio Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Assertio Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Assertio Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Assertio Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Assertio Stock Analysis

When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC